Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4657 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is no specific recommendation regarding pharmacologic treatment as primary prevention for patients with intermediate coronary artery stenosis whose revascularization was deferred based on negative fractional flow reserve (FFR).

Current nationwide cohort study conducted using Korean National Health Insurance Service database evaluated the safety and efficacy of antiplatelet therapy in patients with intermediate coronary artery stenosis with deferred revascularization based on negative FFR (FFR\>0.80).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Research of Resistance to Antiplatelet Agents and Development of Tailored Treatment Model for Patients With Coronary Artery Disease

NCT02121054

Cardiovascular Diseases Coronary Artery Disease

COMPLETED

The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients

NCT03785509

Platelet Aggregation Inhibitors Hydroxymethylglutaryl-coa Reductase Inhibitors Compliance, Medication +3 more

COMPLETED

Effect of Atorvastatin on Fractional Flow Reserve in Coronary Artery Disease

NCT01946815

Coronary Artery Disease

COMPLETED PHASE3

Efficacy Study of Atorvastatin to Treat Variant Angina

NCT00620204

Angina Pectoris, Variant

UNKNOWN PHASE4

Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention

NCT00610870

Angioplasty, Transluminal, Percutaneous Coronary

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was nationwide cohort study conducted using Korean National Health Insurance Service database. From 2013 to 2020, reimbursement criteria of FFR were patients with no previous evidence of myocardial ischemia and intermediate coronary artery stenosis (50-70%). Patients who were evaluated by coronary angiography and FFR but did not undergo revascularization were selected and classified according to the use of antiplatelet agents after index procedure. Patients with previous history of atherosclerotic cardiovascular disease were excluded. Eligible patients were matched using propensity score in a 1:1 ratio. Primary efficacy outcome was major adverse cardiac and cerebrovascular events a composite of all-cause death, myocardial infarction, unplanned revascularization, and stroke at 5-year. Primary safety outcome was gastrointestinal bleeding, regardless of the need of transfusion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Coronary Artery Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Antiplatelet agents

Among patients with intermediate coronary artery stenosis (50-70% diameter stenosis by quantitative coronary angiography) but who did not undergo PCI based on negative FFR, those who were taking antiplatelet agents (aspirin or clopidogrel) are classified into this group.

Antiplatelet Agents

Intervention Type DRUG

Aspirin or clopidogrel

No antiplatelet agents

Among patients with intermediate coronary artery stenosis (50-70% diameter stenosis by quantitative coronary angiography) but who did not undergo PCI based on negative FFR, those who were not taking antiplatelet agents (aspirin or clopidogrel) are classified into this group.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Antiplatelet Agents

Aspirin or clopidogrel

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

aspirin clopidogrel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with 50-70% intermediate stenosis by quantitative coronary angiography in a vessel greater than 2.5 mm
* Patients who underwent invasive coronary angiography and FFR measurement
* Patients whose revascularization was deferred based on FFR\>0.80

Exclusion Criteria

* Patients who underween FFR measurement after expansion of reimbursement criteria of FFR (since 2021)
* Patients with history of any bleeding with blood transfusion
* Patients with use of non-vitamin K antagonist oral anticoagulants (NOAC) or warfarin
* Patients with previous atherosclerotic cardiovascular disease
* Patients with already on antiplatelet agents including dual antiplatelet agents

Eligible Sex

ALL

Accepts Healthy Volunteers

No